Method for Predicting the Response of a Patient Diagnosed with Cancer to Treatment And/or Imaging with a Compound Targeting Cck2-R, and Compound for Use in Methods of Selectively Treating And/or Imaging Cancer

Simple SummaryContent extracted from patent full text and abstract with AI.

This invention provides a method to predict whether a cancer patient will respond to treatment or imaging with compounds targeting the cholecystokinin 2 receptor (CCK2-R), particularly using radiolabeled gastrin analogues. By measuring the mRNA expression of the CCKBR gene in a tumor biopsy and comparing it to a predetermined threshold, clinicians can determine which patients are likely to benefit from targeted treatments or imaging. The invention also covers the use of specific radiolabeled compounds that can selectively bind to CCK2-R, enabling both precise therapeutic intervention and improved imaging of cancers expressing this receptor.

Use CasesContent extracted from patent full text and abstract with AI.

• Personalized selection of cancer patients for peptide receptor radionuclide therapy (PRRT) with CCK2-R targeting compounds.
• Identification of patients most likely to benefit from radiolabeled imaging agents for cancers expressing CCK2-R (e.g., SCLC, GIST, NSCLC, MTC, CRC, breast, and ovarian cancers).
• Companion diagnostic development to guide targeted radiopharmaceutical therapies in oncology.
• Reduction of unnecessary radiation exposure by excluding patients unlikely to benefit from CCK2-R targeting compounds.
• Enhanced tumor imaging for diagnosis, disease monitoring, or therapy planning using specific PET/SPECT tracers.

BenefitsContent extracted from patent full text and abstract with AI.

• Enables precise selection of patients who are most likely to respond to CCK2-R-targeted therapy or imaging, optimizing therapeutic outcomes and minimizing side effects.
• Reduces unnecessary exposure to radiolabeled compounds in patients less likely to benefit, increasing safety.
• Improves accuracy and efficacy of tumor imaging by identifying patients with sufficient CCK2-R expression.
• Provides a robust, reproducible, and easier-to-implement diagnostic biomarker (CCKBR mRNA level) compared to challenging protein-based assays.
• Supports personalized and precision medicine approaches by linking molecular tumor profiling with specific therapeutic decisions.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

A predictive method and a compound for use in treating and/or imaging cancer. The present invention relates to a method for predicting the response of a patient diagnosed with cancer to treatment and/or imaging with a compound targeting cholecystokinin 2 receptor (CCK2R). There is also described a compound targeting CCK2R for use in methods of selectively treating and/or imaging cancer in a patient diagnosed therewith, which leads to improved delivery and therapeutic efficacy and/or enables improved imaging of the tumor tissues.